Adoptive cell transfer with chimeric antigen receptor (CAR)-expressing T cells can induce remarkable complete responses in ...

The study reveals IL-15's role in enhancing GPC3 CAR T cell therapy, improving tumor targeting and T cell survival in ...

Immunotherapies have shaped the cancer research space over the past decade, proving effective for the treatment of some ...

T cells and allogeneic hematopoietic stem cell transplantation. Dr Simonetta's clinical work is mainly focused on Chimeric ...

Researchers report results of the first-in-human phase 1 clinical trials of a novel immunotherapy approach for solid tumors ...

A novel CAR T-cell therapy has benefitted patients with relapsed acute lymphoblastic leukemia, showing high response rates in ...

TUESDAY, Dec. 3, 2024 (HealthDay News) -- A newly approved immunotherapy can help adults with a difficult-to-treat form of ...

Santhosh K. Sadashiv, MD, discusses the role of chimeric antigen receptor T-cell therapy in patients with multiple myeloma.

Patients with relapsed or refractory CD19-positive B-cell acute lymphoblastic leukemia (ALL) who were treated with the novel anti-CD19 chimeric antigen receptor (CAR) T cell therapy, obecabtagene ...

A new chimeric antigen receptor T cell (CAR-T) therapy has delivered promising results in treating patients with an ...

New advances allow scientists to study DNA, RNA, and gene activity in individual cells rather than in bulk tissue samples.

Preclinical studies showed that the addition of IL-15 could improve the performance of CAR T cell-based immunotherapies.